GlassScriptPhysician profile
Alan C Braverman
NPI 1477597805
$7,503.47
in general payments reported to CMS, 2019-2025
12 companies · $3,354 in 2025
The $3,354 reported for 2025 was more than what 89% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $939 · 2022: $916 · 2023: $175 · 2024: $2,119 · 2025: $3,354.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,169 · Food and Beverage: $479.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,169.49 |
| Food and Beverage | $479.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi US Services INC. | $3,200.00 | 2025 | |
| Novartis Pharmaceuticals Corporation | $1,750.00 | 2024 | |
| Spark Therapeutics, INC. | $915.95 | 2022 | |
| W. L. Gore & Associates, INC. | $350.00 | 2019 | |
| Medtronic Vascular, INC. | $333.00 | 2019 | |
| Jenavalve Technology, INC. | $219.49 | 2024 | |
| Boston Scientific Corporation | $175.00 | 2023 | Filterwire Ez |
| Abiomed | $150.00 | 2024 | Impella |
| Abbott Laboratories | $145.54 | 2019 | |
| Philips North America LLC | $110.05 | 2019 | |
| Shockwave Medical, INC | $97.77 | 2025 | |
| Amgen INC. | $56.67 | 2025 | Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Braverman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.